Walleye Capital LLC Altimmune, Inc. Call Options Transaction History

Walleye Capital LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$5.91 - $10.23 $46,689 - $80,817	7,900 Added 225.71%	11,400 $75,000
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $28,770 - $48,335	3,500 New	3,500 $35,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $838 - $3,365	200 New	200 $0
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $167,519 - $351,837	15,700 New	15,700 $200,000

191

42.4M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $371M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.